Associations of high sensitivity C-reactive protein levels in schizophrenia and comparison groups

Schizophrenia Research

Volumn 168, Issue 1-2, 2015, Pages 456-460

  Joseph, Jamie ^a,b   Depp, Colin ^a,b,c   Martin, Averria Sirkin ^a,b   Daly, Rebecca E ^a,b   Glorioso, Danielle K ^a,b   Palmer, Barton W ^a,b,c   Jeste, Dilip V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b San Diego   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Aging; Body mass index; Hs CRP; Inflammation; Metabolic disorders; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; NEUROLEPTIC AGENT; BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HEBEPHRENIA; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RACE DIFFERENCE; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING HABIT; AGED; BLOOD; METABOLIC DISEASES; METABOLISM; MIDDLE AGED; PSYCHOTIC DISORDERS; SEXUAL DEVELOPMENT;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; COMORBIDITY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METABOLIC DISEASES; MIDDLE AGED; OUTPATIENTS; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 84942366069     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.08.019     Document Type: Article

References (42)

1. Akanji A.O., Ohaeri J.U., Al-Shammri S., Fatania H.R. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. 2009, 169(1):56-61. 10.1016/j.psychres.2008.06.010.
2. Almeida O.P., Hankey G.J., Yeap B.B., Golledge J., Norman P.E., Flicker L. Mortality among people with severe mental disorders who reach old age: a longitudinal study of a community-representative sample of 37,892 men. PLoS ONE 2014, 9(10). 10.1371/journal.pone.0111882.
3. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa, Iowa City, IA.
4. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City, IA.
5. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
6. Delis D., Kaplan E., Kramer J. Delis-Kaplan Executive Function Scale (D-KEFS): Examiner's manual 2001, The Psychological Corporation, San Antonio, TX.
7. Demakakos P., Nazroo J., Breeze E., Marmot M. Socioeconomic status and health: the role of subjective social status. Soc. Sci. Med. 2008, 67(2):330-340. 10.1016/j.socscimed.2008.03.038.
8. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93(1-3):261-265.
9. Dickerson F., Stallings C., Origoni A., Schroeder J., Khushalani S., Yolken R. Mortality in schizophrenia: clinical and serological predictors. Schizophr. Bull. 2014, 40(4):796-803. 10.1093/schbul/sbt113.
10. Dickerson F., Stallings C., Origoni A., Vaughan C., Khushalani S., Yolken R. Additive effects of elevated C-reactive protein and exposure to Herpes Simplex Virus type 1 on cognitive impairment in individuals with schizophrenia. Schizophr. Res. 2012, 134(1):83-88. 10.1016/j.schres.2011.10.003.
11. Dietrich T., Garcia R., de Pablo P., Schulze P., Hoffmann K. The effects of cigarette smoking on C-reactive protein concentrations in men and women and its modification by exogenous oral hormones in women. Eur. J. Prev. Cardiol. 2007, 14(5):694-700. 10.1097/HJR.0b013e328270b913.
12. Fan X., Goff D.C., Henderson D.C. Inflammation and schizophrenia. Expert. Rev. Neurother. 2007, 7(7):789-796.
13. Fawzi M.H., Fawzi M.M., Said N.S. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011, 190(1):91-97. 10.1016/j.psychres.2011.05.010.
14. Fawzi M.H., Fawzi M.M., Said N.S., Fawzi M.M., Fouad A.A., Abdel-Moety H. Effect of Ramadan fasting on anthropometric, metabolic, inflammatory and psychopathology status of Egyptian male patients with schizophrenia. Psychiatry Res. 2015, 225(3):501-508. 10.1016/j.psychres.2014.11.057.
15. First M.B., Spitzer R.L., Miriam G., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
16. Fucetola R., Seidman L.J., Kremen W.S., Faraone S.V., Goldstein J.M., Tsuang M.T. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol. Psychiatry 2000, 48(2):137-146.
17. Garcia-Rizo C., Fernandez-Egea E., Oliveira C., Justicia A., Bernardo M., Kirkpatrick B. Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res. 2012, 198(2):212-215. 10.1016/j.psychres.2011.08.014.
18. Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger W.H., Heimovitz H., Cohen H.J., Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 1999, 106(5):506-512.
19. Jin H., Folsom D., Sasaki A., Mudaliar S., Henry R., Torres M., Golshan S., Glorioso D.K., Jeste D. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr. Res. 2011, 125(2-3):295-299. 10.1016/j.schres.2010.10.029.
20. Jones A.L., Mowry B.J., Pender M.P., Greer J.M. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol. Cell Biol. 2005, 83(1):9-17.
21. Kirkpatrick B., Messias E., Harvey P.D., Fernandez-Egea E., Bowie C.R. Is schizophrenia a syndrome of accelerated aging?. Schizophr. Bull. 2008, 34(6):1024-1032.
22. Konishi S., Parajuli R.P., Takane E., Maharjan M., Tachibana K., Jiang H.W., Pahari K., Inoue Y., Umezaki M., Watanabe C. Significant sex difference in the association between C-reactive protein concentration and anthropometry among 13- to 19-year olds, but not 6- to 12-year olds in Nepal. Am. J. Phys. Anthropol. 2014, 154(1):42-51. 10.1002/ajpa.22470.
23. Lopresti A.L., Drummond P.D. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 45:92-99. 10.1016/j.pnpbp.2013.05.005.
24. Manu P., Khan S., Radhakrishnan R., Russ M.J., Kane J.M., Correll C.U. Body mass index identified as an independent predictor of psychiatric readmission. J. Clin. Psychiatry 2014, 75(6):e573-e577. 10.4088/JCP.13m08795.
25. Miller B.J., Culpepper N., Rapaport M.H. C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin. Schizophr. Relat. Psychoses 2014, 7(4):223-230. 10.3371/CSRP.MICU.020813.
26. Miller B.J., Kandhal P., Rapaport M.H., Mellor A., Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. Brain Behav. Immun. 2015, 45:28-35. 10.1016/j.bbi.2014.12.005.
27. Onat A., Can G., Hergenç G., Uğur M., Yüksel H. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference. Nutr. Metab. Cardiovasc. Dis. 2012, 8:643-650. 10.1016/j.numecd.2010.10.010.
28. Palmer B.W., Heaton R.K. Executive dysfunction in schizophrenia. Cognition in Schizophrenia: Impairments, Importance and Treatment Strategies 2000, 52-72. Oxford University Press, New York. T. Sharma, P. Harvey (Eds.).
29. Palmer B.W., Martin A.S., Depp C.A., Glorioso D.K., Jeste D.V. Wellness within illness: happiness in schizophrenia. Schizophr. Res. 2014, 159(1):151-156. 10.1016/j.schres.2014.07.027.
30. Parmelee P.A., Thuras P.D., Katz I.R., Lawton M.P. Validation of the cumulative illness rating scale in a geriatric residential population. J. Am. Geriatr. Soc. 1995, 43(2):130-137.
31. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Investig. 2003, 111(12):1805-1812.
32. Protopopova D., Masopust J., Maly R., Valis M., Bazant J. The prevalence of cardiometabolic risk factors and the ten-year risk of fatal cardiovascular events in patients with schizophrenia and related psychotic disorders. Psychiatr. Danub. 2012, 24(3):307-313.
33. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107(3):363-369.
34. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J. Am. Coll. Cardiol. 2007, 49(21):2129-2138.
35. Rossi I., Bochud M., Bovet P., Paccaud F., Waeber G., Vollenweider P., Taffé P. Sex difference and the role of leptin in the association between high-sensitivity C-reactive protein and adiposity in two different populations. Eur. J. Epidemiol. 2012, 27(5):379-384. 10.1007/s10654-012-9671-0.
36. Rogowski O., Shapira I., Toker S., Melamed S., Shirom A., Berliner S., Zeltser D. Obesity-related correlation between C-reactive protein and the calculated 10-y Framingham Coronary Heart Disease Risk Score. Int. J. Obes. 2005, 29:772-777.
37. Saatcioglu O., Kalkan M., Fistikci N., Erek S., Kilic K. Relationship between metabolic syndrome and clinical features, and its personal-social performance in patients with schizophrenia. Psychiatry Q. 2015, (Epub ahead of print).
38. Sicras-Mainar A., Rejas-Gutierrez J., Navarro-Artieda R., Blanca-Tamayo M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur. Psychiatry 2013, 28(3):161-167. 10.1016/j.eurpsy.2011.07.003.
39. Toomey R., Kremen W.S., Simpson J.C., Samson J.A., Seidman L.J., Lyons M.J., Faraone S.V., Tsuang M.T. Revisiting the factor structure for positive and negative symptoms: evidence from a large heterogeneous group of psychiatric patients. Am. J. Psychiatry 1997, 154(3):371-377.
40. Tracy R., Psaty B., Macy E., Bovill E., Cushman M., Cornell E., Kuller L. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 1997, 17(10):2167-2176. 10.1161/01.ATV.17.10.2167.
41. Tsimikas S., Willerson J.T., Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol. 2006, 47(8 Suppl.):C19-C31.
42. Wobrock T., Ecker U.K., Scherk H., Schneider-Axmann T., Falkai P., Gruber O. Cognitive impairment of executive function as a core symptom of schizophrenia. World J. Biol. Psychiatry 2008, 1-10.